The bio-tech company
Genmab continues to steer its progress in the financial markets and medical research areas through numerous actions. Recently, it initiated a
share capital reduction, cancelling
1.9M shares thereby adjusting its capital base. A fresh focus has been brought about on Genmab's valuation following the recent Ovarian Cancer data with its product Rina S. The company's
price target has been reduced by
61.97% to stand at 34.46. Further, Genmab has successfully completed the reduction of 1.9 million shares, as confirmed by Investing.com. Confidence in Genmab's stocks has been stirred due to anticipated
Epkinly and Petosemtamab readouts. The company's narrative is expected to shift as 2026 catalyst risks build. Noteworthy insight lies in it gaining analyst support from Deutsche Bank due to its Oncology upside. Furthermore,
Wolfe Research and
Wells Fargo have initiated coverage of the company's stock with outperform and overweight ratings respectively. It's worth noting Genmab's
partnership with AI firm Anthropic has also contributed to the bullish sentiment around the company's stock.
Genmab Stocks News Analytics from Tue, 22 Jul 2025 07:00:00 GMT to Fri, 17 Apr 2026 22:21:25 GMT -
Rating 6
